Ensifentrine
- US DailyMed: Ensifentrine
administration
- None
- US: ℞-only[1]
- N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea
- 298680-25-8 Y
E-isomer: 1884461-72-6
- 9934746
- 8110374 Y
- 3E3D8T1GIX
- D11743
- DTXSID00183983
- Interactive image
- Cc3cc(C)cc(C)c3N=c2cc1-c(cc4OC)c(cc4OC)CCn1c(=O)n2CCNC(N)=O
- InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)/b29-23+ Y
- Key:CSOBIBXVIYAXFM-BYNJWEBRSA-N Y
Ensifentrine, sold under the brand name Ohtuvayre, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD) in adults.[1] It is a phosphodiesterase 3 inhibitor and phosphodiesterase 4 inhibitor.[1] It is given by inhalation.[1]
It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4.[2] As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma.[3]
PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect.[2][4]
Medical uses
Ensifentrine is indicated for the maintenance treatment of chronic obstructive pulmonary disease in adults.[1]
History
Ensifentrine was part of a family of compounds invented by Sir David Jack, former head of R&D for GlaxoSmithKline, and Alexander Oxford, a medicinal chemist; the patents on their work were assigned to Vernalis plc.[5][6][7]: 19–20
In 2005, Rhinopharma Ltd, acquired the rights to the intellectual property from Vernalis.[7]: 19–20 Rhinopharma was a startup founded in Vancouver, Canada in 2004 by Michael Walker, Clive Page, and David Saint, to discover and develop drugs for chronic respiratory diseases,[7]: 16 and intended to develop ensifentrine, delivered with an inhaler, first for allergic rhinitis, then asthma, then for COPD.[7]: 16–17 Ensifentrine was synthesized at a contract research organization, under the supervision of Oxford, and was studied in collaboration with Page's lab at King’s College, London.[2] In 2006 Rhinopharma recapitalized and was renamed Verona Pharma plc.[7]
Ensifentrine was approved for medical use in the United States in June 2024.[1][8]
References
- ^ a b c d e f "Ohtuvayre- ensifentrine suspension". DailyMed. 18 June 2024. Retrieved 15 August 2024.
- ^ a b c Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP (August 2006). "The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 840–8. doi:10.1124/jpet.105.099192. PMID 16682455. S2CID 15490792. Archived from the original (PDF) on 2 March 2019.
- ^ Taylor NP (1 October 2015). "Verona sets sights on PhIIb after COPD drug comes through early trial". FierceBiotech.
- ^ Turner MJ, Matthes E, Billet A, Ferguson AJ, Thomas DY, Randell SH, et al. (January 2016). "The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia". American Journal of Physiology. Lung Cellular and Molecular Physiology. 310 (1): L59-70. doi:10.1152/ajplung.00324.2015. PMID 26545902.
- ^ EP 1165558, Oxford AW, Jack D, "Derivatives of pyrimido[6,1-a]isoquinolin-4-one", published 2002-01-02, assigned to Verona Pharma plc
- ^ Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP (August 2006). "The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]". The Journal of Pharmacology and Experimental Therapeutics. 318 (2): 840–848. doi:10.1124/jpet.105.099192. PMID 16682455. S2CID 15490792.
- ^ a b c d e "Proposed Acquisition of Rhinopharma" (PDF). Isis Resources plc. 23 August 2006. Archived from the original (PDF) on 2 March 2016.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration. 29 July 2024. Retrieved 14 August 2024.
- v
- t
- e
- BAY 60-7550
- Carbazeran
- EHNA
- Oxindole
- PDP
- Adibendan
- Amrinone (inamrinone)
- Anagrelide
- Benafentrine
- Bucladesine
- Carbazeran
- Cilostamide
- Cilostazol
- Enoximone
- Ensifentrine
- Imazodan
- KMUP-1
- Meribendan
- Milrinone
- Olprinone
- Parogrelil
- Pimobendan
- Pumafentrine
- Quazinone
- RPL-554
- Siguazodan
- Trequinsin
- Vesnarinone
- Zardaverine
- Apremilast
- Arofylline
- Atizoram
- Benafentrine
- Catramilast
- CC-1088
- CDP-840
- CGH-2466
- Cilomilast
- Cipamfylline
- Crisaborole
- Denbutylline
- Difamilast
- Drotaverine
- Ensifentrine
- Etazolate
- Filaminast
- Glaucine
- HT-0712
- ICI-63197
- Indimilast
- Irsogladine
- Lavamilast
- Lirimilast
- Lotamilast
- Luteolin
- Mesembrenone
- Mesembrine
- Mesopram
- Oglemilast
- Piclamilast
- Pumafentrine
- Revamilast
- Ro 20-1724
- Roflumilast
- Rolipram
- Ronomilast
- RPL-554
- RS-25344
- Tetomilast
- Tofimilast
- YM-976
- Zardaverine
- Acetildenafil
- Aildenafil
- Avanafil
- Beminafil
- Benzamidenafil
- Dasantafil
- Icariin
- Gisadenafil
- Homosildenafil
- Lodenafil
- Mirodenafil
- MY-5445
- Nitrosoprodenafil
- Norcarbodenafil
- SCH-51866
- Sildenafil
- Sulfoaildenafil
- T-0156
- Tadalafil
- Udenafil
- Vardenafil
- BAY 73-6691
- PF-04447943
- Paraxanthine
- Balipodect
- Mardepodect
- Papaverine
- TC-E 5005
- Tofisopam
- Diazepam
- Diprophylline
- DPCPX
- Furafylline
- Lisofylline
- MDL-12330A
- Moxaverine
- Oxagrelate
- Pentifylline
- Proxyphylline
- Quercetin
- Satigrel
- Tolafentrine
- Trapidil